An Open-label Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Pharmacokinetics of Mavacamten in Healthy Participants
Latest Information Update: 09 Nov 2022
At a glance
- Drugs Mavacamten (Primary) ; Charcoal; Sorbitol
- Indications Heart failure; Hypertrophic cardiomyopathy
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 04 Nov 2022 Status changed from recruiting to completed.
- 17 Jul 2022 Planned number of patients changed from 42 to 30.
- 17 Jul 2022 Planned primary completion date changed from 27 Jul 2022 to 28 Jul 2022.